Humanigen Forum: Community User: Rothschild123

Und wenn the Shorts werden covern 🚀

Someone knows something 🧐

Keine News

Gibt's news?

Sieht doch ganz gut aus im roten Markt

Sieht so aus das die erste Zeit nicht soviel geht . Aber ich lass es liegen ;)

Hmm doch verzockt 😩🤔

Das ist ne Pille für “zu Hause”. Humanigen aber für schon hospitalisierten . Diese Kombi könnte die Pandemie endlich beenden, falls beine zugelassen werden 👍

Oct 1 (Reuters) - An antiviral pill developed by U.S. drugmaker Merck & Co (MRK.N) could half the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, with experts hailing it as a potential breakthrough in how the virus is treated. If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19. Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide.

Jetzt ist mir klar, warum die FDA Himanigen erstmal abgelehnt hat… Merck publizierte heute Phase 3 Ergebnisse des antiviralen Covid Medikaments… und US Regierung hat schon 1.7 Mln davon bestellt 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️

MHRA muss sich ja bald äußern

Alle geplante Module wurden MHRA eingereicht. Wurde betont, dass hospitalisierungszahlen in UK steigen und dass MHRA bzw UK ein Leader der Welt in Medikation insbesondere für Covid 19 ist

Kann mir einer kurz sagen was die neue Info ist ? Positiv oder negativ ? 😁 My Englisch is Not so Good ;)

Unglaublich was die Börse heute macht

🦾

We are pleased with the engagement with MHRA and are committed to continue to work with the agency as necessary to enable MHRA to review our application. As the United Kingdom’s Health Secretary recently stated, the UK is leading the world in identifying and rolling out life-saving medicines, particularly for COVID-19,”1 said Cameron Durrant, CEO of Humanigen. “A UK study funded by the Medical Research Council demonstrated benefits of GM-CSF neutralization in hospitalized COVID-19 patients and we believe results of our LIVE-AIR Phase 3 trial of lenzilumab provide further evidence for the benefits of this approach. Thus, we are seeking Conditional Marketing Authorization with a view to bringing lenzilumab to patients in the UK. We note in the UK there have been more than 20,000 new hospitalizations in the month of September and as of September 27th there were 7,007 people currently hospitalized for COVID-19.”2,3